These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22703232)

  • 1. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
    Moi LL; Flågeng MH; Gjerde J; Madsen A; Røst TH; Gudbrandsen OA; Lien EA; Mellgren G
    BMC Cancer; 2012 Jun; 12():247. PubMed ID: 22703232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
    Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
    Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
    Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
    Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
    Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats.
    Zhang X; Cook KL; Warri A; Cruz IM; Rosim M; Riskin J; Helferich W; Doerge D; Clarke R; Hilakivi-Clarke L
    Clin Cancer Res; 2017 Feb; 23(3):814-824. PubMed ID: 28148690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
    Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
    Hilakivi-Clarke L; Wärri A; Bouker KB; Zhang X; Cook KL; Jin L; Zwart A; Nguyen N; Hu R; Cruz MI; de Assis S; Wang X; Xuan J; Wang Y; Wehrenberg B; Clarke R
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27609189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
    Karmakar S; Foster EA; Blackmore JK; Smith CL
    Endocr Relat Cancer; 2011 Feb; 18(1):113-27. PubMed ID: 21059860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.
    Mansour A; Daba A; Baddour N; El-Saadani M; Aleem E
    J Cancer Res Clin Oncol; 2012 Sep; 138(9):1579-96. PubMed ID: 22552717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
    J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin.
    González A; Alvarez-García V; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Barceló EJ; Cos S
    Curr Cancer Drug Targets; 2010 May; 10(3):279-86. PubMed ID: 20370689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
    De Oliveira Andrade F; Yu W; Zhang X; Carney E; Hu R; Clarke R; FitzGerald K; Hilakivi-Clarke L
    Endocr Relat Cancer; 2019 Mar; 26(3):339-353. PubMed ID: 30640711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.